{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:18:39Z","timestamp":1793974719336,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T00:00:00Z","timestamp":1605398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T00:00:00Z","timestamp":1605398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008955","name":"Wilhelmina Kinderziekenhuis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with common variable immunodeficiency (CVID) can develop immune dysregulation complications such as autoimmunity, lymphoproliferation, enteritis, and malignancy, which cause significant morbidity and mortality. We aimed to (i) assess the potential of serum proteomics in stratifying patients with immune dysregulation using two independent cohorts and (ii) identify cytokine and chemokine signaling pathways that underlie immune dysregulation in CVID. A panel of 180 markers was measured in two multicenter CVID cohorts using Olink Protein Extension Assay technology. A classification algorithm was trained to distinguish CVID with immune dysregulation (CVIDid, <jats:italic>n<\/jats:italic>\u2009=\u200914) from CVID with infections only (CVIDio, <jats:italic>n<\/jats:italic>\u2009=\u200916) in the training cohort, and validated on a second testing cohort (CVIDid <jats:italic>n<\/jats:italic>\u2009=\u200923, CVIDio <jats:italic>n<\/jats:italic>\u2009=\u200924). Differential expression in both cohorts was used to determine relevant signaling pathways. An elastic net classifier using MILR1, LILRB4, IL10, IL12RB1, and CD83 could discriminate between CVIDid and CVIDio patients with a sensitivity of 0.83, specificity of 0.75, and area under the curve of 0.73 in an independent testing cohort. Activated pathways (fold change &gt;\u20091.5, FDR-adjusted <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) in CVIDid included Th1 and Th17-associated signaling, as well as IL10 and other immune regulatory markers (LAG3, TNFRSF9, CD83). Targeted serum proteomics provided an accurate and reproducible tool to discriminate between patients with CVIDid and CVIDio. Cytokine profiles provided insight into activation of Th1 and Th17 pathways and indicate a possible role for chronic inflammation and exhaustion in immune dysregulation. These findings serve as a first step towards the development of biomarkers for immune dysregulation in CVID.<\/jats:p>","DOI":"10.1007\/s10875-020-00908-1","type":"journal-article","created":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T00:05:03Z","timestamp":1605398703000},"page":"362-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Targeted Proteomics Reveals Inflammatory Pathways that Classify Immune Dysregulation in Common Variable Immunodeficiency"],"prefix":"10.1007","volume":"41","author":[{"given":"Roos-Marijn","family":"Berbers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Drylewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline M.","family":"Ellerbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris M.","family":"van Montfrans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgil A. S. H.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Martin","family":"van Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baerbel","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Warnatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap M.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nierkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L.","family":"Leavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,15]]},"reference":[{"key":"908_CR1","unstructured":"Immunodeficiencies ES for Diagnostic Criteria PID [Internet]. 2019. Available from: https:\/\/esid.org\/Education\/Diagnostic-Criteria-PID. Accessed 31 July 2020"},{"key":"908_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","volume":"4","author":"FA Bonilla","year":"2016","unstructured":"Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, et al. International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4:38\u201359.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"908_CR3","first-page":"1","volume":"6","author":"YR Li","year":"2015","unstructured":"Li YR, Zhao SD, Li J, Bradfield JP, Mohebnasab M, Steel L, et al. Genetic sharing and heritability of paediatric age of onset autoimmune diseases. Nat Commun. 2015;6:1\u201310.","journal-title":"Nat Commun"},{"key":"908_CR4","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","volume":"119","author":"ES Resnick","year":"2012","unstructured":"Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119:1650\u20138.","journal-title":"Blood."},{"key":"908_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","volume":"112","author":"H Chapel","year":"2008","unstructured":"Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112:277\u201387.","journal-title":"Blood."},{"key":"908_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaci.2013.12.1077","volume":"134","author":"B Gathmann","year":"2014","unstructured":"Gathmann B, Mahlaoui N, G\u00e9rard L, Oksenhendler E, Warnatz K, Schulze I, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:116\u2013126.e11.","journal-title":"J Allergy Clin Immunol"},{"key":"908_CR7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10875-012-9671-6","volume":"32","author":"LJ Maarschalk-Ellerbroek","year":"2012","unstructured":"Maarschalk-Ellerbroek LJ, Hoepelman AIM, Van Montfrans JM, Ellerbroek PM. The spectrum of disease manifestations in patients with common variable immunodeficiency disorders and partial antibody deficiency in a university hospital. J Clin Immunol. 2012;32:907\u201321.","journal-title":"J Clin Immunol"},{"key":"908_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jaip.2017.01.021","volume":"5","author":"JR Hurst","year":"2017","unstructured":"Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, et al. British Lung Foundation\/United Kingdom primary immunodeficiency network consensus statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2017;5:938\u201345.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"908_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10875-012-9755-3","volume":"33","author":"NM Chase","year":"2013","unstructured":"Chase NM, Verbsky JW, Hintermeyer MK, Waukau JK, Tomita-Mitchell A, Casper JT, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol. 2013;33:30\u20139.","journal-title":"J Clin Immunol"},{"key":"908_CR10","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.4049\/jimmunol.178.6.3932","volume":"178","author":"A Giovannetti","year":"2007","unstructured":"Giovannetti A, Pierdominici M, Mazzetta F, Marziali M, Renzi C, Mileo AM, et al. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J Immunol. 2007;178:3932\u201343.","journal-title":"J Immunol"},{"key":"908_CR11","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood.V99.5.1544","volume":"99","author":"K Warnatz","year":"2002","unstructured":"Warnatz K, Denz A, Dr\u00e4ger R, Braun M, Groth C, Wolff-Vorbeck G, et al. Severe deficiency of switched memory B cells (CD27+IgM-IgD-) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002;99:1544\u201351.","journal-title":"Blood."},{"key":"908_CR12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.anai.2017.01.004","volume":"118","author":"S Hartono","year":"2017","unstructured":"Hartono S, Motosue MS, Khan S, Rodriguez V, Iyer VN, Divekar R, et al. Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency. Ann Allergy Asthma Immunol. 2017;118:614\u201320.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"908_CR13","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1182\/bloodadvances.2017012310","volume":"1","author":"A Hayden","year":"2017","unstructured":"Hayden A, Lin M, Park S, Pudek M, Schneider M, Jordan MB, et al. Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH. Blood Adv. 2017;1:2529\u201334.","journal-title":"Blood Adv"},{"key":"908_CR14","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/art.40881","volume":"71","author":"J Wienke","year":"2019","unstructured":"Wienke J, Bellutti Enders F, Lim J, Mertens JS, van den Hoogen LL, Wijngaarde CA, et al. Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation. Arthritis Rheum. 2019;71:1377\u201390.","journal-title":"Arthritis Rheum"},{"key":"908_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41927-019-0053-z","volume":"3","author":"H Kudela","year":"2019","unstructured":"Kudela H, Drynda S, Lux A, Horneff G, Kekow J. Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still\u2019s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol. 2019;3:1\u201311.","journal-title":"BMC Rheumatol"},{"key":"908_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s10875-014-0053-0","volume":"34","author":"FN Varzaneh","year":"2014","unstructured":"Varzaneh FN, Keller B, Unger S, Aghamohammadi A, Warnatz K, Rezaei N. Cytokines in common variable immunodeficiency as signs of immune dysregulation and potential therapeutic targets - a review of the current knowledge. J Clin Immunol. 2014;34:524\u201343.","journal-title":"J Clin Immunol"},{"key":"908_CR17","first-page":"449","volume":"18","author":"N Rezaei","year":"2008","unstructured":"Rezaei N, Aghamohammadi A, Kardar GA, Nourizadeh M, Pourpak Z. T- helper 1 and 2 cytokine assay in patients with common variable immunodeficiency. J Investig Allergol Clin Immunol. 2008;18:449\u201353.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"908_CR18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10875-014-0099-z","volume":"34","author":"Z Hel","year":"2014","unstructured":"Hel Z, Huijbregts RPH, Xu J, Nechvatalova J, Vlkova M, Litzman J. Altered serum cytokine signature in common variable immunodeficiency. J Clin Immunol. 2014;34:971\u20138.","journal-title":"J Clin Immunol"},{"key":"908_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00001","volume":"10","author":"R Polito","year":"2019","unstructured":"Polito R, Nigro E, Pecoraro A, Monaco ML, Perna F, Sanduzzi A, et al. Adiponectin receptors and pro-inflammatory cytokines are modulated in common variable immunodeficiency patients: correlation with Ig replacement therapy. Front Immunol. 2019;10:1\u20138.","journal-title":"Front Immunol"},{"key":"908_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1046\/j.1365-2362.2001.00768.x","volume":"31","author":"T Ueland","year":"2001","unstructured":"Ueland T, Fr\u00f8land SS, Bollerslev J, Aukrust P. Increased levels of biochemical markers of bone turnover in relation to persistent immune activation in common variable immunodeficiency. Eur J Clin Investig. 2001;31:72\u20138.","journal-title":"Eur J Clin Investig"},{"key":"908_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2020.01.046","volume":"146","author":"J Hultberg","year":"2020","unstructured":"Hultberg J, Ernerudh J, Larsson M, Nilsdotter-Augustinsson \u00c5, Nystr\u00f6m S. Plasma protein profiling reflects TH1-driven immune dysregulation in common variable immunodeficiency. J Allergy Clin Immunol. 2020;146:1\u201312.","journal-title":"J Allergy Clin Immunol"},{"key":"908_CR22","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bj\u00f6rkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9:e95192.","journal-title":"PLoS One"},{"key":"908_CR23","unstructured":"Team RC. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2019. https:\/\/www.R-project.org\/. Accessed 31 July 2020"},{"key":"908_CR24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523\u201330.","journal-title":"Bioinformatics."},{"key":"908_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00001","volume":"10","author":"Z Li","year":"2019","unstructured":"Li Z, Ju X, Silveira PA, Abadir E, Hsu WH, Hart DNJ, et al. CD83: activation marker for antigen presenting cells and its therapeutic potential. Front Immunol. 2019;10:1\u20139.","journal-title":"Front Immunol"},{"key":"908_CR26","doi-asserted-by":"publisher","first-page":"eaat3356","DOI":"10.1126\/scitranslmed.aat3356","volume":"11","author":"LC Berkhout","year":"2019","unstructured":"Berkhout LC, L\u2019Ami MJ, Ruwaard J, Hart MH, Ooijevaar-De Heer P, Bloem K, et al. Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Sci Transl Med. 2019;11:eaat3356.","journal-title":"Sci Transl Med"},{"key":"908_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1084\/jem.20030973","volume":"200","author":"E Zinser","year":"2004","unstructured":"Zinser E, Lechmann M, Golka A, Lutz MB, Steinkasserer A. Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83. J Exp Med. 2004;200:345\u201351.","journal-title":"J Exp Med"},{"key":"908_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.abb.2004.02.042","volume":"425","author":"K Akasaki","year":"2004","unstructured":"Akasaki K, Nakamura N, Tsukui N, Yokota S, Murata SI, Katoh R, et al. Human dendritic cell lysosome-associated membrane protein expressed in lung type II pneumocytes. Arch Biochem Biophys. 2004;425:147\u201357.","journal-title":"Arch Biochem Biophys"},{"key":"908_CR29","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.4049\/jimmunol.0901982","volume":"183","author":"Y Kochi","year":"2009","unstructured":"Kochi Y, Myouzen K, Yamada R, Suzuki A, Kurosaki T, Nakamura Y, et al. FCRL3, an autoimmune susceptibility gene, has inhibitory potential on B-cell receptor-mediated signaling. J Immunol. 2009;183:5502\u201310.","journal-title":"J Immunol"},{"key":"908_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation \u2013 A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"},{"key":"908_CR31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jaci.2017.04.041","volume":"141","author":"S Unger","year":"2018","unstructured":"Unger S, Seidl M, van Schouwenburg P, Rakhmanov M, Bulashevska A, Frede N, et al. The TH1 phenotype of follicular helper T cells indicates an IFN-\u03b3\u2013associated immune dysregulation in patients with CD21low common variable immunodeficiency. J Allergy Clin Immunol. 2018;141:730\u201340.","journal-title":"J Allergy Clin Immunol"},{"key":"908_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00281-019-00733-8","volume":"41","author":"K Yasuda","year":"2019","unstructured":"Yasuda K, Takeuchi Y, Hirota K. The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol. 2019;41:283\u201397.","journal-title":"Semin Immunopathol"},{"key":"908_CR33","doi-asserted-by":"publisher","first-page":"e22848","DOI":"10.1371\/journal.pone.0022848","volume":"6","author":"RR Barbosa","year":"2011","unstructured":"Barbosa RR, Silva SP, Silva SL, Melo AC, Pedro E, Barbosa MP, et al. Primary B-cell deficiencies reveal a link between human IL-17-producing CD4 T-cell homeostasis and B-cell differentiation. PLoS One. 2011;6:e22848.","journal-title":"PLoS One"},{"key":"908_CR34","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.3389\/fimmu.2019.02593","volume":"10","author":"ESJ Edwards","year":"2019","unstructured":"Edwards ESJ, Bosco JJ, Aui PM, Stirling RG, Cameron PU, Chatelier J, et al. Predominantly antibody-deficient patients with non-infectious complications have reduced naive B, Treg, Th17, and Tfh17 cells. Front Immunol. 2019;10:2593.","journal-title":"Front Immunol"},{"key":"908_CR35","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.jaci.2015.09.013","volume":"137","author":"M Cols","year":"2016","unstructured":"Cols M, Rahman A, Maglione PJ, Garcia-Carmona Y, Simchoni N, Ko HBM, et al. Expansion of inflammatory innate lymphoid cells in patients with common variable immune deficiency. J Allergy Clin Immunol. 2016;137:1206\u20131215.e6.","journal-title":"J Allergy Clin Immunol"},{"key":"908_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20190418","volume":"217","author":"M Saraiva","year":"2020","unstructured":"Saraiva M, Saraiva M, Vieira P, Vieira P, Vieira P, O\u2019Garra A, et al. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020;217:1\u201319.","journal-title":"J Exp Med"},{"key":"908_CR37","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm1492","volume":"12","author":"DG Brooks","year":"2006","unstructured":"Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MBA. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12:1301\u20139.","journal-title":"Nat Med"},{"key":"908_CR38","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/mi.2016.18","volume":"9","author":"SF Jorgensen","year":"2016","unstructured":"Jorgensen SF, Troseid M, Kummen M, Anmarkrud JA, Michelsen AE, Osnes LT, et al. Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunol. 2016;9:1455\u201365.","journal-title":"Mucosal Immunol"},{"key":"908_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","volume":"21","author":"CT Huang","year":"2004","unstructured":"Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21:503\u201313.","journal-title":"Immunity."},{"key":"908_CR40","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989\u20131004.","journal-title":"Immunity."},{"key":"908_CR41","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1016\/j.vaccine.2006.03.050","volume":"24","author":"S Fougeray","year":"2006","unstructured":"Fougeray S, Brignone C, Triebel F. A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: preclinical evaluation of IMP321. Vaccine. 2006;24:5426\u201333.","journal-title":"Vaccine."},{"key":"908_CR42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5483\/BMBRep.2014.47.3.283","volume":"47","author":"DS Vinay","year":"2014","unstructured":"Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep. 2014;47:122\u20139.","journal-title":"BMB Rep"},{"key":"908_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ebiom.2020.102647","volume":"52","author":"A Fr\u00f6hlich","year":"2020","unstructured":"Fr\u00f6hlich A, Loick S, Bawden EG, Fietz S, Dietrich J, Diekmann E, et al. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine. 2020;52:1\u201314.","journal-title":"EBioMedicine."},{"key":"908_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/emm.2004.2","volume":"36","author":"HW Jung","year":"2004","unstructured":"Jung HW, Choi SW, Choi JIL, Kwon BS. Serum concentrations of soluble 4-1BB, and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med. 2004;36:13\u201322.","journal-title":"Exp Mol Med"},{"key":"908_CR45","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1084\/jem.20140039","volume":"211","author":"M Perreau","year":"2014","unstructured":"Perreau M, Vigano S, Bellanger F, Pellaton C, Buss G, Comte D, et al. Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. J Exp Med. 2014;211:2033\u201345.","journal-title":"J Exp Med"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-020-00908-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-020-00908-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-020-00908-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T21:12:19Z","timestamp":1612386739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-020-00908-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,15]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["908"],"URL":"https:\/\/doi.org\/10.1007\/s10875-020-00908-1","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,15]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"PH reports research grants and personal fees from Shire\/Takeda and CSL Behring. VD reports research grants and personal fees from Shire\/Takeda, Griffols, ACtelion, Novartis and CSL Behring. JM reports personal fees from Shire\/Takeda. AvdV reports personal fees from CSL Behring. HL reports research grants and personal fees from Shire\/Takeda. All other authors report no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}